semaglutide for dementia Study finds Novo Nordisk's Ozempic may reduce Study finds some weight loss

Retatrutide is still investigational and not widely approved for clinical use, whereas Tirzepatide is already approved and more widely accessible

Its cardiovascular benefit data established in the SELECT trial (2023), demonstrating a significant reduction in major cardiovascular events in adults with obesity without diabetes is more mature than tirzepatides cardiovascular outcomes data, which is accumulating but more recent

Sun F, Chai S, Yu K, Quan X, Yang Z, Wu S, et al

Side effects timeline: what to expect and when Side effects follow their own week-by-week pattern that is just as important to understand as the weight loss timeline